The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents  by Oronsky, Bryan T. et al.
The Scarlet Letter of Alkylation:
A Mini Review of Selective
Alkylating Agents
Bryan T. Oronsky*, Tony Reid†, Susan J. Knox‡
and Jan J. Scicinski*
*RadioRx, Inc, Mountain View, CA; †Moores Cancer
Center, University of California – San Diego, La Jolla, CA;
‡Department of Radiation Oncology, Stanford University
Medical Center, Stanford, CA
Abstract
If there were a stigma scale for chemotherapy, alkylating agents would be ranked at the top of the list. The chemical
term alkylation is associated with nonselective toxicity, an association that dates back to the use of nitrogenmustards
during World War I as chemical warfare agents. That this stigma persists and extends to compounds that, through
selectivity, attempt to “tame” the indiscriminate destructive potential of alkylation is the subject of this review. Selective
alkylation, as it is referred to herein, constitutes an extremely nascent and dynamic field in oncology. The pharmaco-
dynamic response to this selective strategy depends on a delicate kinetic balance between specificity and the rate and
extent of binding. Three representative compounds are presented: RRx-001, 3-bromopyruvate, and TH-302. The main
impetus for the development of these compounds has been the avoidance of the serious complications of traditional
alkylating agents; therefore, it is the thesis of this review that they should not experience stigma by association.
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Introduction
“Many people refused to interpret the scarlet A by its original
signification. They said that it meant Able; so strong was
Hester Prynne, with a woman’s strength.”
Nathaniel Hawthorne, The Scarlet Letter
In the classic novel, The Scarlet Letter, by Nathaniel Hawthorne,
set in 17th-century Puritan Boston, adulteress Hester Prynne must
wear a scarlet A to mark her shame. In the 21st century, this theme
of ostracization is recapitulated in the context of medical oncology
where the mark of sin, the scarlet letter A, is worn by a polygamously
promiscuous class of compounds called alkylating agents. Nevertheless,
there has been a recent upsurge in interest in drugs that covalently and
irreversible bind to their target [1–3].
In chemistry, alkylation denotes the covalent linkage, referred to as an
adduct, of a positively charged or electron-deficient carbon to a lone pair
of electrons on a C, N, O, S, or another atom in an organic molecule.
In oncology, the term alkylating agent refers to any antineoplastic
compound that irreversibly binds to a variety of susceptible bio-
molecules such as nucleic acids, proteins, amino acids, and nucleo-
tides. This covalent interaction mediates cell death through interference
with DNA structure and function, inactivation of DNA repair enzymes,
and cell membrane damage.
The traditional alkylators such as the nitrogen mustards react with
nucleophilic sites in DNA (usually the N7 position of guanine)
through one or more electron-deficient alkyl groups [4]. This mech-
anism is distinct from the platinum analogs such as cisplatin and
carboplatin, which, although loosely described as alkylating agents,
bind to the N7 position of guanine and/or adenine bases in its DNA
target through the platinum atom.
These typical cytotoxic alkylating agents such as the mustards react
nonselectively on dosing, binding irreversibly not just to DNA but
also to protein thiols. Although this effect is responsible for activity,
it also gives rise to the many and rather unpleasant side effects, such
as neutropenia and myelosuppression. As a consequence of their toxi-
cological profile, alkylating agents have long had a bad name: As a
class, alkylating agents are stigmatized and stereotyped with a reputa-
tion for indiscriminate tissue toxicity and unpredictable biologic effects
resulting in off-target effects and idiosyncratic toxicity. This negative
reputation is a potential bias and barrier to the development of com-
pounds, whatever their principal mechanisms of action, which may
contain an alkylating center.
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The key to successful development outcomes for compounds
that bind irreversible is selectivity. This can be achieved in one of
two ways. Singh et al. [3] proposed a strategy that achieves selectiv-
ity for covalent binding by optimizing the fit of the molecule at the
binding site and exploiting a nucleophilic amino acid in the active
site to irreversibly bind to an electrophilic group in the drug, “lock-
ing” the molecule into the active site. A weak alkylator is therefore
acceptable so long as it can bind strongly but reversibly through
another locus to its substrate enabling the alkylation centers to react
through a proximity effect with the protein nucleophile. However,
selectivity can also be achieved by combining high reactivity with
good permeability characteristics. This results in the rapid delivery
of the drug to its site of action where it binds quickly and irrevers-
ibly to its target, thereby minimizing off-target effects that can lead
to toxicity.
Unfortunately and unfairly, even agents that avoid the problem of
indiscriminate tissue toxicity by selectively alkylating specific thera-
peutic targets are potentially tarred with the same stigmatized brush.
This review examines three examples of selective alkylating agents,
grouped on the basis of their mechanism of action and their specific
nucleophilic affinity. These examples belong to three different classes: 1)
the antienergetics, 2) redox modifiers, and 3) tumor DNA prodrugs.
These representative compounds are RRx-001, 3-bromopyruvate
(3-BrPA), and TH-302 (Figure 1).
The Long “Fuse” of Traditional Alkylating Agents
Chemically, an alkylating agent may be considered to have two parts: a
fuse known as the leaving group, which will depart during the alkyl-
ation reaction to expose a warhead in the form of an active alkyl ion
or radical. Positively charged alkyl groups are electrophilic, meaning
they are attracted to electron-rich atoms or nucleophiles.
In vivo, the most abundant nucleophiles are thiols present partic-
ularly in glutathione and amines present in peptides, free amino
acids, and N-containing building blocks in nucleic acids such as
the nitrogen atom at the seventh position (N7) of guanine and adenine.
Thiols are generally more reactive nucleophiles than amines.
Leaving groups are defined as a molecular fragment that is detached
by the action of nucleophiles [5].
The shorter the fuse, that is, the faster the leaving group departs,
the faster the electron-negative alkyl warhead will react in vivo with
nucleophiles. The ability of a leaving group to depart is influenced by
the polarizability and the strength of the carbon-leaving group bond
and the stability of the displaced group.
Traditional alkylating agents such as the nitrogen mustard analogs,
nitrosoureas, aziridines, and epoxides are highly diffusible and easily
penetrate cells [6]. These are relatively unreactive and, like a variable
time–delayed fuse, the departure of their leaving groups is followed
by the activation of the alkylating center in the electron-rich intra-
cellular milieu, leading to a wide spectrum of off-target toxicities.
In the selective alkylation strategies presented in this review, the
alkyl warhead is armed with a more predictably calibrated departure
of the leaving group, resulting in a narrower spectrum of drug action.
The Short Fuse of RRx-001, a Prooxidant
Vascular-Modifying Agent
RRx-001, a novel phase 1 anticancer agent sourced from the defense
industry, is an α-bromoacetyl derivative that is selectively and specif-
ically reactive through an SN2 mechanism (Figures 2 and 3) with free
thiols such as reduced glutathione, cysteine, and the β-93 cysteinyl res-
idue of hemoglobin [7].
Although a detailed description of the molecular mechanism of
alkylation is outside the scope of this review, alkylation pathways more
Figure 1. RRx-001, 3-BrPA, and TH-302.
Figure 2. SN1 (1) and SN2 (2) reaction pathways.
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generally involve first-order nucleophilic substitution (SN1; Figure 2)
and second-order nucleophilic substitution (SN2; Figure 2) reactions.
The kinetics of the RRx-001 reaction, believed to be SN2, is de-
pendent on the concentration of the nucleophile, namely, thiol, and
the reactivity of the leaving group, namely, bromine:
rate = k½R − Br½SH− 
The quasi-immediate departure of the bromide-leaving group on
infusion (within seconds) of RRx-001 results in rapid reaction. Im-
portantly, the balance of reactivity against permeability ensures that
RRx-001 is able to diffuse into red blood cells and react selectively
resulting in the generation of stable sulfhydryl and hemoglobin ad-
ducts. Because RRx-001 irreversibly binds to thiols rather than DNA
and RNA, the typical toxicities associated with alkylating oncologic
agents such as myelosuppression and immunosuppression are absent.
Indeed, in preclinical studies, RRx-001 demonstrated tumor cyto-
toxicity in the absence of the toxicities normally associated with
alkylating agents that typically arise from DNA functionalization
(RadioRx, unpublished data, 2012). Although RRx-001 binds to
hemoglobin, no hemoglobinopathies or significant hemodynamic
toxicities were observed up to toxic levels in animals.
The leaving group ability of bromine is modulated by the strong
electron-withdrawing gem-dinitro group on the azetidine ring at
the distant end of the molecule. Owing in part to the presence of
these NO donor moieties that are selectively released in the tumor,
RRx-001, through a “bystander effect,” leads to redistribution of
tumor blood flow.
The compound is representative of a new therapeutic paradigm link-
ing highly selective alkylation with tumor microenvironment-targeted
treatment in the absence of typical chemotherapeutic toxicities.
The Selectivity of the Antienergetic, 3-BrPA
Like RRx-001, the pyruvate analog, 3-BrPA, reacts selectively
through an SN2 mechanism with thiol groups because of the rapid
dissociation of its bromo-leaving group, exposing an alkylating cen-
ter that depletes ATP through inhibition of the glycolytic enzymes
3-glyceraldehyde phosphate dehydrogenase and hexokinase (Figure 3).
Also similar to RRx-001, the reactivity of Br is influenced by the in-
ductive withdrawal of electron density due to the polarity of the
C=O double bonds.
Because of its structural similarity to lactate, 3-BrPA may enter
cancer cells on the same transporter that exports lactate [8]. In effect,
3-BrPA is a prodrug that is activated at the “just-right” moment by
in vivo cleavage of its “goldilocks”-leaving group, Br, in the presence
of the target enzymes, 3-glyceraldehyde phosphate dehydrogenase
and hexokinase (Figure 3). In preclinical studies, 3-BrPA had sig-
nificant in vivo therapeutic activity without apparent toxicity against
carcinoma models as an “antienergetic” when administered locally
or systemically [8–10].
In preclinical studies, 3-BrPA was particularly effective when
dosed intra-arterially. In the rabbit VX2 hepatoma model, 3-BrPA
was infused intra-arterially and was found to inhibit the viability of
the tumor cells without altering the viability of the surrounding liver
tissue [10]. In a subsequent study, the rate of infusion was found to
be an important factor for minimizing peripheral liver cell necrosis
[11]. Targeted alkylation of cancer cell metabolism through an inher-
ent leaving group–activated prodrug approach, dosing locally or sys-
temically, therefore represents a novel chemistry-based strategy to
decrease systemic toxicity while enhancing activity.
TH-302 Alkylation Prodrug
Like RRx-001, which contains two pharmacophores with separate
modes of action, TH-302 combines two different and independently
functioning anticancer compounds, bromo-isophosphoramide, a
Figure 3. Mechanism of activation and binding for 3-BrPA (1), RRx-001 (2), and TH-302 (3).
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nitrogen mustard, and 2-nitroimidazole into one hybrid molecule that
is linked with a bioreductively cleavable chemical bridge. Under deeply
hypoxic conditions endemic only to tumors, the 2-nitroimidazole,
a substrate for intracellular one-electron reductases, is activated
and “pushes” electrons into a redox-active linker, releasing bromo-
isophosphoramide (Figure 3) [12].
The nitroimidazoles belong to a class of compounds called oxygen
mimetics that undergo enzymatic and radiation-induced redox reac-
tions but have little intrinsic unactivated activity [13]. Although the
alkylating nature of the TH-302 “warhead” would be expected to pre-
dominantly account for activity [13], it could be expected that the
nitroimidazole functionality may also contribute to the tumoricidal
effect at sufficiently elevated doses.
TH-302 has demonstrated activity in patients as monotherapy and
in combination in multiple tumor types including pancreatic cancer,
metastatic melanoma, non–small cell lung cancer, hormone refractory
prostate cancer, relapsed/refractory acute myeloid leukemia and acute
lymphoblastic leukemia, and soft tissue sarcoma for which it was
granted orphan drug status in combination with doxorubicin. Merck
recently acquired the worldwide rights for TH-302.
Conclusions
By the end of the novel, The Scarlet Letter, the “A” worn by the pro-
tagonist is transformed into a symbol of pride rather than shame. A
similar denouement is hoped for and anticipated with selective alkylat-
ing agents. From their origins as an indiscriminate weapon in World
War I to their conversion as an indiscriminate weapon against cancer,
alkylating agents have been feared for their Dr Jekyll-and-Mr Hyde
character almost as much as the disease they are used to treat.
However, the development of a new generation of selective alky-
lating agents should result in a critical reevaluation of the status of
this class of therapeutic drug. The three compounds discussed in this
review, RRx-001, 3-Br-PA, and TH-302, are at the leading edge of
this evolution.
Through the addition of prodrug-like moieties, it is possible to turn
the double-edged sword of alkylation into a surgical blade, minimiz-
ing the damage to healthy, normal tissue while maximizing destruc-
tion of the tumor. Ironically, the covalent, irreversible “marriage” of
alkylation agents to their nucleophilic substrates may result in less col-
lateral damage than the rapid and promiscuously reversible association
of small molecules such as the kinase inhibitors with multiple ligands.
From vascular and redox modulation to ATP depletion and hypoxia
activation, the approaches to treatment may differ, but the overall
strategy is the same: activation of the alkylation scaffold in the right
time, in the right place, and in the right subset of tumor types.
The success of TH-302 and the promising clinical and preclinical
activity of RRx-001 and 3-BrPA, respectively, prove not only that an
old therapeutic dog can be taught new tricks but also that, as a poten-
tially transformative paradigm, selective alkylation will lead to novel
“designer” therapies that offer the promise of tremendous benefit to
present and future patients.
References
[1] Guterman L (2011). Covalent drugs form long-lived ties—irreversible inhibitors
may provide unique benefits in drug development. Chem Eng News 89, 19–26.
[2] Potashman MH and Duggan ME (2009). Covalent modifiers: an orthogonal
approach to drug design. J Med Chem 52, 1231–1246.
[3] Singh J, Petter RC, Baillie TA, and Whitty A (2011). The resurgence of cova-
lent drugs. Nat Rev Drug Discov 10, 307–317.
[4] Siddik ZH (2002). Mechanisms of action of cancer chemotherapeutic agents:
DNA-interactive alkylating agents and antitumour platinum-based drugs. In
The Cancer Handbook. Nature Publishing Group, London, UK. pp. 1295–1313.
[5] Lepore SD and Mondal D (2007). Recent advances in heterolytic nucleofugal
leaving groups. Tetrahedron 63, 5103–5122.
[6] Warwick GP (1963). The mechanism of action of alkylating agents. Cancer Res
23, 1315–1333.
[7] Scicinski J, Oronsky B, FitchW, Taylor M, Luo G,Musick T,Marini J, Adams C,
Schicker M, Gohdes M, et al. (2011). Disposition of 14C-RRx-001 in rats after a
single intravenous administration and in blood from rats, dogs, monkeys, and
humans. In 17th North American Regional ISSX Meeting, Atlanta, GA p. P81.
[8] Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J,
and Pedersen PL (2004). Advanced cancers: eradication in all cases using
3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324,
269–275.
[9] Mathupala SP, Ko YH, and Pedersen PL (2009). Hexokinase-2 bound to mito-
chondria: cancer’s stygian link to the “Warburg effect” and a pivotal target for
effective therapy. Semin Cancer Biol 19, 17–24.
[10] Geschwind JF, Ko YH, Torbenson MS, Magee C, and Pedersen PL (2002).
Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor
of ATP production. Cancer Res 62, 3909–3913.
[11] Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C,
and Geschwind JF (2007). Intraarterial therapy with a new potent inhibitor of
tumor metabolism (3-bromopyruvate): identification of therapeutic dose and
method of injection in an animal model of liver cancer. J Vasc Interv Radiol
18, 95–101.
[12] Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons
WS, Curd JG, Matteucci MD, et al. (2011). Selective tumor hypoxia targeting
by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models
of cancer. Clin Cancer Res 18, 758–770.
[13] Oronsky BT, Knox SJ, and Scicinski J (2011). Six degrees of separation:
the oxygen effect in the development of radiosensitizers. Transl Oncol 4,
189–198.
Translational Oncology Vol. 5, No. 4, 2012 Selective Alkylating Agents – Mini Review Oronsky et al. 229
